Accumulating evidence indicates that progestins are involved in controlling mammary gland tumorigenesis. Here, we assessed the molecular mechanisms of progestin action in breast cancer models with different phenotypes. We examined C4HD cells, an estrogen (ER) and progesterone (PR) receptor-positive murine breast cancer model in which progestins exert sustained proliferative response, the LM3 murine metastatic mammary tumor cell line, which lacks PR and ER expression, and human PR null T47D-Y breast cancer cells. In addition to acting as a transcription factor, PR can also function as an activator of signaling pathways. To explore which of these two functions were involved in progestin responses, reconstitution experiments in the PR-negative models were performed with wild-type PR-B, with a DNA binding mutant C587A-PR, and with mutant PR-BmPro, which lacks the ability to activate cytoplasm signaling pathways. We found that in a cell context either ER-positive or -negative, progestins induced cell growth and modulation of matrix metalloproteinases-9 (MMP-9) and -2 (MMP-2), and urokinase-type plasminogen activator ( P ROGESTERONE PLAYS A key role in the regulation of cell proliferation and differentiation in the mammary gland, as demonstrated, among an increasing body of evidence, by incomplete mammary gland ductal branching and failure of lobulo-alveolar development in progesterone receptor (PR) knockout mice (1, 2). Accumulated findings indicate that progestins are also involved in controlling mammary gland tumorigenesis both in women and in animal models (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Progestin effects in vitro growth of breast cancer cells were found to be highly dependent on experimental culture conditions and on the presence of estrogens. Particularly, progestins were found to either support sustained growth (11) or to induce cells to progress through one round of cell division, followed by growth arrest at the G1/S phase of the second cycle (6, 15) in the human breast cancer cell line T47D, the ideal model of breast cancer cell with estrogen receptor (ER)-independent, constitutive expression of PR-A and PR-B. Seminal work by Horwitz and co-workers (6, 8, 15, 16) provided evidence that the initial pulse of 
Accumulating evidence indicates that progestins are involved in controlling mammary gland tumorigenesis. Here, we assessed the molecular mechanisms of progestin action in breast cancer models with different phenotypes. We examined C4HD cells, an estrogen (ER) and progesterone (PR) receptor-positive murine breast cancer model in which progestins exert sustained proliferative response, the LM3 murine metastatic mammary tumor cell line, which lacks PR and ER expression, and human PR null T47D-Y breast cancer cells. In addition to acting as a transcription factor, PR can also function as an activator of signaling pathways. To explore which of these two functions were involved in progestin responses, reconstitution experiments in the PR-negative models were performed with wild-type PR-B, with a DNA binding mutant C587A-PR, and with mutant PR-BmPro, which lacks the ability to activate cytoplasm signaling pathways. We found that in a cell context either ER-positive or -negative, progestins induced cell growth and modulation of matrix metalloproteinases-9 (MMP-9) and -2 (MMP-2), and urokinase-type plasminogen activator (uPA) activities, via MAPK and phosphatidylinositol 3-kinase/Akt pathways, in cells expressing wildtype PR-B or DNA binding mutant C587A-PR. In contrast, in cells expressing mutant PR-BmPro, progestins did not induce growth. We also found that unliganded PR expression conferred breast cancer cells an in vitro less proliferative phenotype, as compared with cells lacking PR expression. Modulation of this behavior occurred when PR was functioning either as transcription factor or as signaling activator. Finally, we for the first time demonstrated that progestins favor development of breast tumor metastasis via PR function as activator of signaling pathways. Our present findings provide mechanistic support to the design of a novel therapeutic intervention in PR-positive breast tumors involving blockage of PR capacity to activate cytoplasmic signaling. (Molecular Endocrinology 21: 1335-1358, 2007) P ROGESTERONE PLAYS A key role in the regulation of cell proliferation and differentiation in the mammary gland, as demonstrated, among an increasing body of evidence, by incomplete mammary gland ductal branching and failure of lobulo-alveolar development in progesterone receptor (PR) knockout mice (1, 2) . Accumulated findings indicate that progestins are also involved in controlling mammary gland tumorigenesis both in women and in animal models (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Progestin effects in vitro growth of breast cancer cells were found to be highly dependent on experimental culture conditions and on the presence of estrogens. Particularly, progestins were found to either support sustained growth (11) or to induce cells to progress through one round of cell division, followed by growth arrest at the G1/S phase of the second cycle (6, 15) in the human breast cancer cell line T47D, the ideal model of breast cancer cell with estrogen receptor (ER)-independent, constitutive expression of PR-A and PR-B. Seminal work by Horwitz and co-workers (6, 8, 15, 16) provided evidence that the initial pulse of progestins primes progesterone-arrested cells for the action of secondary proliferative or differentiative signaling pathways. Hence, the commitment to one path or the other would be determined by cross talk between growth factor/cytokine pathways and by progesterone/PR signaling (6, 15, 16) . Several lines of evidence, including our own work, (17) (18) (19) have shown that convergence between progestins and type I receptor tyrosine kinases mediates proliferative effects of progestins in breast cancer cells (8, 15) . Recently, strong evidence of progestin implication in breast cancer etiology was provided by the observation that postmenopausal women who undergo a combined estrogen and progestin hormone replacement therapy suffer a higher incidence of breast cancer than women who take estrogen alone (20, 21) .
The classical pathway of progesterone inducible PR-mediated gene transcription has long been described. Upon progesterone binding, PR undergoes a conformational change, dissociates from a multiprotein chaperone complex, dimerizes and binds to specific progesterone response elements (PREs) in the promoter of target genes (22) . DNA-bound receptor recruits coactivators that facilitate transcription initiation through interaction with components of the basal transcription machinery (23) . In addition to their direct transcriptional effects, rapid or nongenomic biological effects of progestins have been described in breast cancer cells, evidencing that progestin treatment of human breast cancer T47D cells, activates the signaltransducing c-Src/p21 ras /MAPK pathway which results in cell proliferation (13, 14, 24) . Particularly interesting is the interaction between PR and c-Src kinase because it has been demonstrated that activation of c-Src in breast cancer cells is a critical event in tumor progression (3, 14, (25) (26) (27) . A series of previous studies demonstrated that transfection with dominant-negative c-Src significantly reduced cell spreading, migration and proliferation of MCF7 and MDA-MB-468 cells (28, 29) . Furthermore, c-Src kinase activity is associated with tumor cell colonization in bone and lung (30) and with cell invasion and metastasis of breast cancer cells (31, 32) . Hence, activation of c-Src/MAPK signaling pathway mediated by progesterone receptor may contribute to multiple aspects of breast cancer progression.
Although progestins were found to enhance growth and to act as survival factors of breast cancer cells (11) , the molecular mechanisms through which progestins control breast cancer growth and metastasis still remain elusive. On the other hand, the presence of PR in breast tumors, regardless of ER expression, is associated with response to hormonal therapy and good prognosis (33, 34) , underscoring the complex role of PR in mammary cancer.
In the present study, we took advantage of three breast cancer models with different phenotypes to study molecular mechanisms of progestin action in mammary tumor cell growth, proteases activity, and development of metastasis. The first model examined were primary cultures of C4HD cells, our well-described ER-, and PR-positive murine breast cancer model in which progestins exert sustained proliferative response both in vitro and in vivo (17-19, 35, 36) . The second was our well-characterized model of metastasis for mammary cancer, the LM3 murine cell line (37) . The LM3 mammary tumor cell line, which lacks PR and ER expression, derives from the M3 mouse mammary adenocarcinoma (37) . Like its parental tumor LM3 cells exhibits a highly invasive behavior and 90-100% incidence of lung metastasis (37) . Finally, we studied human PR null T47D-Y breast cancer cells (8, 38, 39) . Reconstitution experiments in our PR-negative models were performed with wild-type PR-B (10, 40) , DNA binding mutant C587A-PR (3), and mutant PR-BmPro devoid of the ability to activate c-Src-dependent signaling (3) . Our results demonstrated that, either in an ER-positive or -negative cell context, progestins induced proliferation and regulated proteases activity and metastasis through PR ability to activate c-Srcdependent signaling pathways. In addition, in the course of the present study we were able to show that unliganded PR expression conferred breast cancer cells an in vitro less proliferative phenotype, as compared with cells lacking PR expression. Modulation of this behavior occurred through PR functioning as either transcription factor or signaling activator. Our present findings could lead to a novel therapeutic approach in PR-positive breast tumors through blockage of PR capacity to activate c-Src-dependent signaling pathways. ras /MAPK pathway in the proliferative phase of the biphasic T47D human breast cancer cell response to progestins (14, 41) . We here took advantage of a well-described model of hormonal carcinogenesis, in which the response of breast cancer cells to progestins is sustainedly proliferative, to investigate progestin effect on MAPK activity. We worked with primary cultures of the C4HD murine mammary tumor line from an experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice (17-19, 35, 36) . As we have previously described in detail (17-19, 35, 36) , C4HD epithelial cells derive from a ductal, progestin-dependent mammary tumor line. C4HD cells require MPA administration to proliferate both in vitro and in vivo and express high levels of PR-B, PR-A, and ER␣ (17-19, 35, 36) . As shown in Fig. 1A , MPA was able to induce rapid phosphorylation of p42/p44 MAPK (2-fold) in C4HD cells, detected by using antisera specific for the active dually phosphorylated form of this kinase. MPAinduced activation was observed as early as 5 min after treatment and returned to basal levels after 30 min. Pretreatment of C4HD cells with 10 M PD98059, a specific inhibitor of MEK1, or with 5 M U0126, a MEK1/MEK2 inhibitor, suppressed activation of MAPKs by MPA (Fig. 1A) . At concentrations of either 10 nM (not shown) or 100 nM, progestin antagonist RU486 did not induce MAPK activation but significantly inhibited MPA-stimulation of MAPK activity (Fig.  1A) . Progestin regulation of PI-3K/Akt pathway activity in breast cancer still remains poorly explored (42) . Therefore, we here investigated PI-3K/Akt activation status by performing Western blots with an antiphosphoserine 473 Akt antibody, as marker of Akt activation. As we had already found in our in vivo studies (36) , MPA was able to induce strong Akt phosphorylation after 5 min treatment, with the highest phosphorylation level (3-fold) observed at 10 min (Fig. 1B) . Wortmannin (1 M) and LY294002 (2 M), specific chemical inhibitors of PI-3K, completely blocked MPA-induced Akt phosphorylation (Fig. 1B) . Treatment of C4HD cells with RU486 did not result in stimulation of Akt activity, but significantly inhibited MPA capacity to induce Akt activation (Fig. 1B) . Blockage of MAPK activation with PD98059 or U0126 had no effect on MPA capacity to stimulate Akt phosphorylation and similarly inhibition of Akt activity with wortmannin or LY294002 caused no effect on MPA-induced MAPK phosphorylation (data not shown).
RESULTS

Progestins
Results obtained with progestin antagonist RU486 strongly suggested that classical, nuclear PR is mediating nongenomic MPA-induced p42/p44 MAPK and PI-3K/Akt pathways activation. Therefore, to further demonstrate involvement of conventional PR, we used as a second experimental model our well-characterized mouse metastatic mammary tumor line LM3, which lacks PR and ER expression (37) . The LM3 mammary tumor cell line derives from the M3 mouse mammary adenocarcinoma (37) . Like its parental tumor LM3 cells exhibits a highly invasive behavior and 90-100% incidence of lung metastasis (37) . Finally, we used as the third model system, the human PR null A, Primary cultures of C4HD cells were treated with 10 nM MPA for the indicated times and with 100 nM RU486 for 5 min, or pretreated with 100 nM RU486, 10 M PD98059, or 5 M U0126 before MPA stimulation. Twenty-five micrograms of protein from cell lysates were electrophoresed and Western blot assay was performed with antiphospho-p42/p44MAPK antibody. Membranes were then stripped and hybridized with anti-p42/p44MAPK antibody. B, C4HD cells were treated with 10 nM MPA and 100 nM RU486 or pretreated with 100 nM RU486, 1 M Wortmannin, or 2 M LY294002 before adding MPA. Fifty micrograms of protein from cell lysates were electrophoresed and Western blot was performed with antiphosphoserine 473 Akt antibody. Membranes were then stripped and hybridized with anti-Akt antibody. Phospho MAPK and Akt bands underwent densitometry and values were normalized to total MAPK or Akt protein bands. Data analysis showed that increase in MAPK (5-30 min) and Akt phosphorylation (5-30 min) in cells treated with MPA, as compared with untreated cells, and inhibition of MPA-induced phosphorylation levels caused by the respective pharmacological inhibitor and by RU486 were significant (P Ͻ 0.001). Experiments shown in A and B were repeated five times with similar results. T47D-Y cells that possess ER␣ (8) . We first transiently transfected LM3 cells with a human PR-B (hPR-B) expression vector (8) . As shown in Fig. 2A , MPA rapidly stimulated c-Src phosphorylation of PR-B-transfected LM3 cells (LM3-PR-B). In addition, whereas MPA was not able to induce p42/p44 MAPK phosphorylation in wild-type LM3 cells (Fig. 2B ), 5 min of MPA treatment stimulated p42/p44 MAPK phosphorylation in LM3-PR-B cells (Fig. 2B) . Preincubation of LM3-PR-B cells with U0126 completely blocked MPAinduced phosphorylation of p42/p44 MAPK, even below the levels of unstimulated cells (Fig. 2B ). RU486 caused lower but still significant inhibition of MPA ability to induce MAPK activation in LM3-PR-B cells, as compared with the pharmacological inhibitor U0126 (Fig. 2B) . RU486, at concentrations of either 10 nM (not shown) or 100 nM, did not induce MAPK activation in LM3-PR-B cells (Fig. 2B) . Finally, using our third experimental model, we were also able to detect significant induction of p42/p44 MAPKs phosphorylation by MPA treatment of T47D-Y cells transfected with the hPR-B (T47D-Y-PR-B), which was completely blocked by U0126 and significantly inhibited by RU486 (Fig. 2C ). Lange and co-workers (41) recently reported RU486 capacity to induce p42/p44 MAPK activation in T47D stably expressing PR-B or the S294A mutant PR-B. Here, we could not detect reproducible induction of p42/p44 MAPKs activation by RU486 in T47D-Y cells transiently transfected with PR-B (Fig. 2C) . Assessment of PI-3K/Akt activity showed that MPA was not able to induce Akt phosphorylation in wildtype LM3 cells or in T47D-Y cells (Fig. 2, D and E, respectively). However, MPA induced Akt Ser 473 phosphorylation in LM3-PR-B cells, which was abrogated by specific PI-3K/Akt inhibitor LY294002 (Fig.  2D ). RU486 alone did not induce Akt phosphorylation but inhibited MPA stimulatory effect (Fig. 2D) . MPA also induced Akt phosphorylation in T47D-Y-PR-B cells, which was suppressed by LY294002 and significantly inhibited by RU486 (Fig. 2E) . Stimulation with RU486 alone did not result in Akt phosphorylation (Fig. 2E) .
To further evidence progestin ability to activate cytoplasmic kinases by a nongenomic mechanism, we transfected LM3 and T47D-Y cells with a PR-B engineered to contain a point mutation in a conserved cysteine in the first zinc finger of the DNA binding domain (C587A) that was engineered and characterized by Horwitz and co-workers (43) and lacks capacity to bind to PRE. As reported in Cos-7 cells (3), MPA treatment of LM3 cells transfected with C587A-PR (LM3-C587A-PR) resulted in rapid induction of c-Src phosphorylation (Fig. 3A) . In addition, MPA exerted a reproducible increase in p42/p44 MAPK phosphorylation in LM3-C587A-PR cells, which was abolished by U0126 and inhibited by RU486 (Fig. 3B) . We also found significant induction of p42/p44 MAPK phosphorylation by MPA treatment of T47D-Y cells transfected with the C587A-PR (T47D-Y-C587A-PR), which was completely blocked by U0126 and significantly inhibited by RU486 (Fig. 3C ). MPA treatment also induced reproducible Akt phosphorylation in LM3-C587A-PR (Fig. 3D ) and T47D-Y-C587A-PR (Fig. 3E) cells, that was abrogated by LY294002 and inhibited by RU486 (Fig. 3, D 
and E).
Expression and function of wild-type PR-B and C587A-PR-B under the conditions described above, in which they modulate MAPK and PI-3K/Akt activation, were then assessed. As shown in Fig. 4 , A (LM3 cells) and B (T47D-Y cells), transfection of cells with both plasmids resulted in dose-dependent induction of PR expression. As a measure of PR-B functional activity in transfected LM3 cells, the significant down-regulation of PR-B exerted by 48 h MPA treatment is shown in Fig. 4A (lanes 3 and 4) . On the contrary, MPA did not significantly down-regulate C587A-PR-B expression (Fig. 4A, lanes 6 and 7) . However, C587A-PR-B underwent MPA-induced changes in electrophoretic mobility of PR on sodium dodecyl sulfate (SDS)-gels, resulting in an upward shift, associated with a second step of ligand-induced increase in PR phosphoryla- Fig. 3 clearly demonstrated that both are strong activators of p42/p44 MAPK and PI-3K/Akt signaling pathways. In addition, we found that transient transfection of LM3-PR-B cells with a PRE-2X-TATA-luciferase reporter plasmid (10) resulted in strong MPA induction of the PRE reporter construct (Fig. 4C) . As previously reported when engineering the C587A-PR construct (43) , no transcriptional activity of this mutated PR was detected when transfected in LM3 cells (Fig. 4C) . We also explored C587A-PR transcriptional activity on an endogenous gene. Because progesterone induction of Bcl-x L expression in breast cancer cells is well acknowledged (11) , and the Bcl-x L contains a PRE sequence (44), we examined the effects of C587A-PR on Bcl-x L protein expression. As shown in Fig. 4D (left panel), MPA treatment of LM3-PR-B resulted in significant induction of Bcl-x L expression. On the contrary, MPA capacity to induce Bcl-x L protein in LM3-C587A-PR was significantly lower, as compared with LM3-PR-B cells (Fig. 4D , left panel). We had already expected this attenuated response. Even diminished, this response was still present because progestin capacity to activate signaling pathways acting through C587A-PR could induce the activation of different transcription factors that in turn regulate Bcl-x L transcription through binding to this gene promoter. To further characterize C587A-PR with regard to its ability to modulate endogenous gene expression, we chose to study also p21 protein expression. The promoter of p21 lacks a canonical PRE, but progestin regulates its transcription through a tethering mechanism in which PR interacts with the p21 promoter through the transcription factor Sp1 at the third and fourth of six Sp1 binding sites (45) . In their original description of C587A-PR mutant, Horwitz and her co-workers (43), using PRE containing constructs, reported that PREindependent transcription requires an intact receptor DNA binding domain and therefore C587A-PR mutant was unable to regulate this kind of transcriptional mechanism. A likely mechanism for the PRE-independent transcription is factor tethering, in which two factors establish protein-protein contact on the DNA, but only one of them binds DNA. However, the two proteins involved in this transcriptional mechanism, the one that binds DNA and its associated protein, possess a DNA binding domain. Because the C587A-PR mutant lacks an ordered first zinc finger and therefore a functional DNA binding domain, we hypothesized that its capacity to regulate p21 expression through tethering will be strongly impaired as compared with wild type PR-B. Indeed, results shown in Fig. 4D (right panel) confirm our hypothesis. As previously reported in T47D-Y cells stably expressing PR-B and stimulated with either progesterone (6) or the synthetic progestin R5020 (41), we found here that MPA treatment of LM3-PR-B cells induced a significant increase in the levels of p21 protein that peaked at 36 h after MPA stimulation. Contrastingly, we were not able to detect significant MPA capacity to induce p21 expression in LM3-C587A-PR ( 
Blockage of MAPKs and PI-3K Activity Inhibits MPA-Induced Proliferation of Mammary Tumor Cells
We have long demonstrated that MPA exerts a potent and sustained proliferative effect on C4HD cells that is completely abolished by RU486 (17) (18) (19) 35) . Because MPA was able to activate both MAPK and PI-3K/Akt pathways, we decided to investigate whether blockage of these two signaling pathways would inhibit MPA-induced proliferation of C4HD cells. As shown in Fig. 5 A, MPA induction of C4HD cell growth was significantly inhibited by PD98059 (45 Ϯ 6%) and Twenty-five micrograms of protein from cell lysates were electrophoresed and Western blot assay was performed with antiphospho-c-Src antibody. Membranes were stripped and hybridized with anti-c-Src antibody. The experiment shown was repeated five times with similar results. B and C, LM3 (B) and T47D-Y (C) cells were transfected with the C587A-PR mutant (LM3-C587A-PR and T47D-Y-C587A-PR), or remained untreated. Cells were then stimulated for 5 min with 10 nM MPA and 100 nM RU486 or pretreated with 5 M U0126 or 100 nM RU486 before MPA stimulation. Twenty-five (LM3 cell types) or 50 (T47D-Y cell types) g of protein from lysates were electrophoresed and Western blot assays were performed with antiphospho p42/p44MAPK antibody. Membranes were then stripped and hybridized with anti-p42/p44MAPK antibody. D and E, LM3 (D) and T47D-Y (E) cells transfected as described in B and C were treated for 5 min with 10 nM MPA and RU486 or pretreated with 2 M LY294002 or 100 nM RU486 before MPA stimulation. Western blot assays were performed using an antiphosphoserine 473 Akt antibody. Membranes were stripped and hybridized with anti-Akt antibody. Phospho-MAPK and Akt bands underwent densitometry and were analyzed as described in Fig. 1 showing that MPA-induced increase in MAPK and Akt phosphorylation in cells transfected with the C587A-PR mutant and inhibition of MPA-induced phosphorylation levels caused by the respective pharmacological inhibitor and by RU486 were significant (P Ͻ 0.001). Experiments shown in B-E were repeated five times for each cell type with similar results.
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Actin Western blot assay using antiactin antibody was carried out using identical protein lysates as control of specificity of PR expression and MPA treatment. C, LM3 cells were transiently transfected with 2 g of a PRE-2X-TATA-luciferase reporter plasmid and with 1 g of cytomegalovirus-␤gal expression vector as internal control. Cells were cotransfected with 40 ng of PR-B, C587A-PR, or pSG5 empty vector. After transfection, cells were treated with MPA and MPAϩRU486 for 48 h, or were left untreated. Cells were then harvested and lysed. Luciferase and ␤-galactosidase activities were measured as described in Materials and Methods. Results are presented as fold induction of luciferase activity with respect to cells growing in absence of U0126 (50 Ϯ 7%) and by the two specific PI3K inhibitors, wortmannin (40 Ϯ 5%) and LY294002 (44 Ϯ 6%). Neither PD98059 or U0126, nor wortmannin or LY294002 had any effect on basal C4HD cell proliferation (Fig. 5A ). In addition, RU486 did not stimulate C4HD cell growth (Fig. 5A) . These results were obtained with 48 h of progestin treatment. As expected, exactly same results were obtained when C4HD cells were treated for 24 h with MPA because we have extensively demonstrated that MPA induces proliferation of primary cultures of C4HD cells through all time these cultures are maintained (17) (18) (19) 35) . To further explore involvement of cytoplasmic signaling pathways in MPA-induced growth, we studied progestin effects in LM3-PR-B cell growth. As shown in Fig. 5B , basal LM3-PR-B cell proliferation was significantly lower than that of wild-type LM3 cells or LM3 transfected with empty pSG5 vector, clearly showing that PR-B expression significantly reduced LM3 cell proliferation. MPA treatment did not induce wild-type LM3 cell growth, but significantly stimulated LM3-PR-B cell proliferation (Fig. 5B ). RU486 inhibited MPA capacity to induce LM3-PR-B cell growth but did not affect basal LM3-PR-B cell proliferation (Fig. 5B) . Abolishment of MAPK activity with U0126 or of PI-3K with LY294002 had no effect on basal LM3-PR-B cell growth, but resulted in significant inhibition of MPAinduced proliferation of these cells (Fig. 5B) . In addition, neither U0126 nor LY294002 at the concentrations used in Fig. 5B , affected wild-type LM3 or LM3-pSG5 cell proliferation (data not shown). Similar results were found when we transfected LM3 cells with the C587A-PR vector, showing that C587A-PR expression significantly reduced LM3 cell proliferation and that response of LM3-C587A-PR cells to MPA is proliferative (Fig. 5C ). As in LM3-PR-B cells, RU486 alone did not induce LM3-C587A-PR cell proliferation and significantly inhibited MPA capacity to induce LM3-C587A-PR cell growth (Fig. 5C ). In addition, blockage of MAPK or PI-3K/Akt pathways strongly decreased LM3-C587A-PR cell proliferation (Fig. 5C) . Notably, when LM3 cells expressed mutant PR-BmPro, devoid of the ability to activate c-Src-dependent signaling pathways (3), basal proliferation was significantly lower as compared with wild-type LM3 cells but no proliferation in response to MPA was found (Fig.  5C ). As can be seen, levels of expression of PR-B and PR-BmPro were comparable (Fig. 5D, left panel) . In addition, both receptors exhibited the characteristic upshift in electrophoretic mobility, associated with phosphorylation, and significant down-regulation after MPA treatment (Fig. 5D, left panel) . We also found that PR-BmPro is still able to regulate transcription of the p21 promoter via the tethering mechanism. Thus, MPA treatment of LM3-PR-BmPro cells induced a significant increase in the levels of p21 protein that peaked at 36 h after MPA stimulation (Fig. 5D, right panel) . As control, we are also showing lack of MPA capacity to induce MAPK and PI-3K/Akt activation in LM3-PRBmPro cells (Fig. 5E ). We also explored MPA effects in LM3 cell survival by using a clonogenic assay that indicates cell surviving at extremely stringent conditions because it is performed plating cells at a very low density. At the end of the experiment the number of surviving colonies is counted. Regarding cell proliferation assays, the main difference between them is that the clonogenic assay evaluates both cell proliferation and survival capacity. Hence, using this assay, we also found that survival of LM3-PR, LM3-C587A-PR and LM3-PR-BmPro cells was significantly lower as compared with either wild-type LM3 or LM3 transfected with the empty vector (Fig. 5F ). MPA significantly increased survival of both LM3-PR and LM3-C587A-PR cells, but no difference in the number of surviving colonies was observed in LM3-PR-BmPro cells after MPA treatment (Fig. 5F ). Results obtained in T47D-Y cells transfected with hPR-B (Fig. 5G) or with C587A-PR (Fig.  5H) showed that MPA treatment also induced cell proliferation, which was significantly inhibited by RU486, U0126, and LY294002. None of these pharmacological inhibitors affected wild-type T47D-Y or T47D-Y-pSG5 cell growth (data not shown). As expected, T47D-Y-PRmPro cells proliferation was not affected after MPA treatment (Fig. 5H) . Similar results regarding PR-BmPro expression and function were found in T47D-Y cells as compared with those described in LM3 cells (data not shown). Studies in LM3 and T47D-Y cells were done treating cells for 24 h with MPA because it has been demonstrated that at this time point T47D-Y-PR-B cell response to progestins is proliferative. Therefore, we have used the same time point in both of our reconstitution models. These results can be easily compared with findings in C4HD cells because as we explained above, C4HD cell growth responses at 24 and 48 h of 
Actin progestins treatment are similar. Our present findings clearly indicate that PR ability to activate MAPK and PI-3K/Akt signaling cascades mediates MPA-induced breast cancer cell growth. Additional support to these findings, was provided by our previous findings (17, 18) showing that blockage of MAPK activity did not inhibit MPA capacity to activate the PRE-LUC reporter. We also found that abolishment of PI-3K/Akt signaling did not consistently modify MPA-induced PR transcriptional activity either (data not shown). Similarly, neither preincubation with PD98059 or U0126, nor wortmannin or LY294002 had any effect on PR protein levels or in MPA capacity to down-regulate PR protein levels after 48 h of incubation (data not shown).
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MPA Inhibits Urokinase-Type Plasminogen Activator (uPA), Matrix Metalloproteinases (MMP)-9 and -2 Activities via Nongenomic Mechanisms
Whereas overall effects of progestins on invasion and metastasis in breast cancer remain poorly studied, progesterone was found to inhibit uPA secretion as well as MMP-9 and MMP-2 activities in human endometrial and ovarian carcinoma cells (46) (47) (48) . Therefore, we here investigated MPA effects on uPA, MMP-9, and MMP-2 secreted activities in our MPA-induced mammary tumor model. Proteolytic activity was evaluated by gelatin or casein zymography in conditioned media from C4HD cells growing under serum-free conditions or stimulated with MPA. As shown in Fig.  6A , treatment of C4HD cells with 10 nM MPA for 24 h resulted in significant reduction of MMP-9 (44% Ϯ 6), MMP-2 (58% Ϯ 7) and uPA (51 Ϯ 6%) activities. Treatment of C4HD cells with RU486 alone had no effect on proteases secretion (Fig. 6A) . However, MPA inhibition of uPA and MMPs activities was completely blocked by the progestin antagonist (Fig. 6A) . To determine MPA effects on MMPs and uPA secreted protein levels and protein expression, we performed Western blots using either C4HD cell conditioned media or whole cell extracts. As happened with their activities, MMP-9, MMP-2, and uPA secreted protein levels ( Fig. 6B ) and protein expression (Fig. 6C) were significantly reduced after treatment of C4HD cells with 10 nM MPA. We then investigated involvement of MAPK and PI-3K/Akt signaling pathways in MPA-induced inhibition of proteases activity. Blockage of PI-3K/Akt signaling resulted in abrogation of MPA inhibitory effect on MMPs activity but had no effect on MPA inhibition of uPA (Fig. 6D) . On the contrary, incubation of C4HD cells with U0126 blocked MPA inhibition of uPA activity but had no effect on MMPs inhibition by MPA (Fig. 6D) . In addition, we observed that neither U0126 nor LY294002 alone had any effect on MMPs and uPA activities (Fig. 6D) . To further explore PR involvement by either transcriptional or nongenomic mechanism in the regulation of the metastatic phenotype, we took advantage of the metastatic LM3 mammary tumor cells. We have already shown that LM3 cells display high levels of uPA activity (49) . Therefore, we explored MPA capacity to regulate uPA activity in LM3-PR-B and LM3-C587A-PR cells. As shown in Fig.  7A , uPA caseinolytic activity was significantly lower after MPA treatment of LM3-PR cells (35 Ϯ 4%). Comparable results were obtained in LM3-C587A-PR cells in which MPA also inhibited uPA activity by 37 Ϯ 5%, indicating progestin ability to regulate uPA activity by a nongenomic mechanism (Fig. 7A) . We then evaluated the participation of p42/p44 MAPK and PI-3K/Akt signaling pathways in MPA-induced inhibition of uPA activity. As can be seen in Fig. 7B , preincubation of LM3-PR-B and LM3-C587A-PR cells with U0126 blocked MPA inhibition of uPA activity. Similarly, LY294002 treatment resulted in abrogation of MPA inhibitory effect in both LM3 transfected cells (Fig. 7C) . This is the first description of progestin regulation of MMPs and uPA via nongenomic mechanisms involving activation of MAPK and PI-3K/Akt in breast cancer cells.
PR Expression Modulates in Vivo Metastatic Development
Because in vitro results with the LM3 experimental model of metastasis indicated that expression of wildtype PR-B and either C587A-PR or PR-BmPro mutants decreased basal LM3 cell proliferation, we investigated the metastatic behavior of LM3 cells transiently transfected with all three PR-B variants. We here used an in vivo experimental metastasis system in which we evaluated the ability of LM3 tumor cells to form lung metastases (50) (51) (52) (53) . In this type of metastasis assay, cells are injected into animals directly into circulation, thus omitting the first stages of the metastatic cascade and therefore modeling the latter phases of the process (50, 52, 53) . The end point of the assay is the formation of visible metastases at a secondary site (50) . It has been well demonstrated that once in the blood circulation, the majority of cells quickly arrest in the first capillary bed they encounter and extravasate into the target organ (reviewed in Ref. 51) , that in the case of LM3 cells is the lung (37) . In a series of elegant studies, the fate of different metastatic cell types, including mouse melanomas, Ras-transformed mouse fibroblasts, and mouse mammary carcinomas, after their injection into the circulation, has been followed over time using quantitative cell-fate analysis and in vivo videomicroscopy (reviewed in Ref. 51) . Results indicated that between 87 and 98% of the injected cells were arrested in the target organ 60-90 min after injection (52, 53) . In addition, it has been found that, for example for B16F1 murine melanoma cells, 3 d after injection, 83% of the cells that were originally injected had extravasated into the liver parenchyma and remained there (52, 53) . Therefore, these and other studies have shown that steps of arrest in the organ and extravasation are highly efficient (51) (52) (53) . These works have also shown that subsequent steps, involving initiation of growth to form micrometastasis and sustained growth and development of new blood vessels to form macroscopic metastases, are considerable less efficient and have evidenced that the final outcome of the metastatic process depends on the regulation of the early growth of a subpopulation of cells arrested in the secondary site (52, 53) . In our present model, the efficient and rapid steps of arrest and extravasation will be likely completed when the injected cells still express the transfected PRs because we have found that LM3 cells transiently transfected with wild-type or mutant PRs, still express high levels of PR protein 1 wk after transfection (Fig. 8) . In addition, 10 d after transfection, we were also able to detect low levels of PRs expression, which was undetectable after 14 d in culture. In this study, 3 ϫ 10 5 wild-type LM3 cells or the same number of LM3-PR-B, LM3-C587A-PR, LM3-PR-BmPro, and LM3 cells transfected with the empty pSG5 vector, were injected into the tail vein of syngeneic mice. These cells were therefore exposed to physiological levels of circulating progesterone in the intact animal, which present an average value of 5 ng/ml. To test the effect of exogenous progestin administration, the same experimental design was carried out in animals treated sc with 40 mg MPA depot. We have previously reported that MPA serum levels in these animals were 49 ng/ml, which are not physiological levels of progestins (54) . At d 28 mice were killed and the number of superficial lung colonies was determined. As shown in Table 1 , a significant decrease in the number of metastatic foci was observed in mice inoculated with LM3-PR-B, LM3-C587A-PR, or PR-BmPro cells, as compared with mice injected with LM3 wild-type cells or LM3 cells transfected with empty vector. Notably, LM3-PR-BmPro cells showed metastatic capacity lower not only than cells expressing wild-type PR-B but also than cells transfected with C587A-PR. When LM3-PR-B and LM3-C587A-PR-positive cells were inoculated in mice treated with the MPA pellet, higher metastasis development was observed, as compared with their respective counterpart growing in mice to which no exogenous MPA was administered (Table 1) . On the contrary, no modulation of metastatic foci number was observed when LM3-PR-BmPro cells were injected in mice treated with MPA. As expected in an experimental metastasis assay for aggressive tumor cells, after 28 d of injection, the incidence of metastasis varied between 90 and 100%. In fact only 1/10 mice inoculated with LM3-PR-BmPro cells (either treated or not with MPA) did not develop lung nodes. In addition, we found no significant differences in metastasis size among groups. When we examined lung metastasis in mice injected with PR-expressing LM3 cells, using immunohistochemistry, we could not detect PR expression (data not shown). It is highly probable that through these 28 d, cells have lost PR expression. This finding, however, does not invalidate our results because, taking into account the studies we mentioned above, in this type of experimental metastasis assay, the metastatic capacity of the different LM3 cell types is defined during the first days of the study, in which cells retain PR expression. To provide further support to our findings that PR expression is causally related to the modulation of the metastatic phenotype, we performed the same experimental approach but mice were killed at d 7. At this time point, transfected cells still express high levels of PRs (Fig. 8) . As shown in Table 2 , although as expected the number of macroscopic metastasis was lower than in the experiment ended at d 28, similar results regarding PR reduction of lung metastasis were observed in both experimental designs.
DISCUSSION
Progestins Induce Nongenomic Activation of Both p42/p44 MAPKs and PI-3K/Akt Signaling Pathways in Breast Cancer Acting through the Classical PR, Independently of ER␣ Expression
In the present study, we demonstrated that MPA induced rapid, nongenomic activation of both p42/p44 MAPK and PI-3K/Akt signaling pathways in C4HD cells, a breast cancer model in which progestins exert sustained proliferative response. MPA effects on these pathways were mediated by the classical intracellular PR, as demonstrated by the results obtained with progestin transcriptional antagonist RU486 and by reconstitution experiments in the LM3 murine metastatic mammary tumor cell line, which lacks PR and ER expression, and in human PR null T47D-Y cells. Thus, expression of either wild-type PR-B or the DNA binding mutant C587A-PR rendered LM3 and T47D-Y cells capable to respond to MPA with rapid activation of p42/p44 MAPK and PI-3K/Akt. Nongenomic effects of progestins in breast cancer cells have been unraveled by startling reports from Auricchio and co-workers (13, 14, 24) who demonstrated that progestin treatment of human breast cancer T47D cells activates the signaltransducing c-Src/p21 ras /MAPK pathway, which results in cell proliferation (13, 14) . These authors have shown that progestin's ability to activate c-Src/MAPK pathway depends on the presence of unliganded ER␣, which is the one that activates c-Src. ER␣ and PR-B interaction occurs via two domains that flank the PR proline-rich sequence (24) . On the other hand, direct interaction of the polyproline motif of PR-B with the SH3 domain of c-Src, which results in c-Src activation by a SH3 displacement mechanism, has been found in vitro, in human normal breast MCF-12 cells transduced with PR-B, and in T47D cells (3) . In these two cell types, interaction is progestin dependent (3). As a consequence of c-Src activation, p42/p44 MAPK phosphorylation occurs in MCF-7 cells stably expressing PR-B (3). In addition, PR-B expression increased c-Src activity in COS-7 cells in the absence of progestins and independently of cotransfection with ER (3). In these studies, expression of both ER and PR reduced basal levels of c-Src activity, turning progestin ability to induce c-Src activation readily detectable (3). Our present results in LM3-PR-B and LM3-C587A-PR cells are in accordance with these latter findings, supporting a model in which activation by progestins of the c-Src/MAPK pathway can be exerted independently of ER␣. To reconcile the above discrepancies between progestin direct or indirect activation of c-Src, it has recently been suggested that a plethora of signaling complexes may result depending on the presence of different signaling and adaptator molecules in a given cell type (55) .
Progestin regulation of PI-3K/Akt pathway activity in breast cancer remains poorly explored (42) . To our knowledge, we were the first to demonstrate that in breast tumors MPA activates the PI-3K/Akt signaling pathway, which participates in progestininduced in vivo growth (36) . Our present in vitro findings demonstrated that MPA induced Akt phosphorylation in cells expressing both wild-type PR-B and C587A-PR. These results are in agreement with recent findings showing progesterone and MPA capacity to induce rapid phosphorylation of Ser473 Akt in B-474, T47Dco cells and T47D-Y cells stably transfected with PR-B (42). Little is known about RU486 capacity to modulate signaling pathways in breast cancer cells. We here found that when administered alone, RU486 was unable to induce either p42/p44 MAPK or PI-3K/Akt activation in any of the cell types studied. As previously reported in several breast cancer cell lines (14, 41) , RU486 antagonized MPA-induced MAPK activation in all three model systems used in the present work. Notably, Lange and co-workers (41) recently reported that RU486 activated p42/p44 MAPK in T47D cells stably expressing either PR-B or a transcriptionally impaired PR-B harboring a point mutation at Ser294, a ligand-dependent and MAPK consensus phosphorylation site. RU486 was also found to stimulate p42/ p44 MAPK activation in PR-transfected MDA-MB-231 breast cancer cells (56) . Differences between endogenous levels of PR expression in C4HD cells or transient PR expression in LM3 or T47D-Y cells used in our study, and stable expression of PR from a constitutive promoter in T47D-YB (41) or in MDA-MB-231A cells (56) could account for the discrepancies observed in RU486 modulation of p42/p44 MAPK activation. We also found that RU486 antagonized MPA effect on PI-3K/Akt activity in C4HD and LM3 or T47D-Y cells transfected with either wild-type PR-B or C587A-PR. To the best of our knowledge, ours is the first description of the role of antiprogestins in progestin-induced PI-3K/Akt activity in breast cancer. Physical association between Xenopus PR and active PI-3K was found in progesterone-stimulated Xenopus laevis oocyte maturation (57) . However, no association was found in oocytes induced to mature with RU486 (57), in accordance with our present findings, showing that RU486 did not induce PI-3K/Akt activity in breast cancer. In the above early report, RU486 did not modulate proges- 
LM3 cells (3 ϫ 10 5 ) transfected as described in Table 1 were injected into the tail vein of syngeneic mice and the number of experimental lung metastasis was evaluated at d 7 after injection. Same experimental design was carried in animals treated sc with 40 mg MPA depot (ϩMPA). Each experimental group consisted of 10 mice. The number of superficial lung nodules was counted and expressed as median and range. terone stimulated PI-3K activity in XPR immunoprecipitates (57) .
Progestin Regulation of Breast Cancer Growth and Metastatic Phenotype Depends on PR Function as Either Transcription Factor or as Activator of Signaling Pathways
Our present findings have provided new insight into the complex role of PR in breast cancer biology. Firstly, our results in C4HD cells clearly evidenced that progestins are able to induce sustained breast cancer cell proliferation acting through the classical PR via nongenomic mechanisms involving activation not only of MAPK, as has been well documented (3, 14, 41) , but also through the PI-3K/Akt pathway. Furthermore, our reconstitution studies using wild-type PR-B and DNA binding mutant C587A-PR, clearly demonstrated that once PR with full capacity to activate signaling pathways is expressed in either an ER-negative (LM3 cells) or -positive (T47D-Y cells) cell context, progestins are strongly proliferative. Notably, when LM3 cells expressed mutant PR-BmPro, which lacks the ability to activate cytoplasmic signaling pathways, the proliferative response to MPA was lost, in accordance with recent findings in MCF-7 cells stably expressing PRBmPro (41). Startling findings have also shown that PR-BmPro caused delayed progestin-mediated initiation of Xenopus oocyte germinal vesicle breakdown and delayed progestin-induced growth arrest in normal breast epithelial MCF-12 cells, as compared with effects exerted by wild-type PR-B (3). On one hand, our findings are in accordance with accumulated evidence demonstrating progestins' positive role in breast cancer development (11, 12, 14, 41) , mainly through PR capacity to activate cytoplasmic kinases (14, 41) . On the other, they clearly show that cell response to progestins will rely on whether PR functions as a transcription factor or as an activator of signaling cascades. It is to be noted that DNA binding mutant C587A accumulates in the nucleus, but unlike endogenously expressed PR in C4HD or wild-type PR-B transfected in LM3 cells, C587A does not patch at foci (data not shown), which are considered active transcription sites (58, 59) . Furthermore, C587A-PR capacity to induce Bcl-x L protein expression in response to MPA was strikingly lower as compared with wild-type PR-B. Here, we found that RU486 alone did not regulate growth of C4HD cells or of LM3 and T47D-Y cells transfected with either wild-type PR-B or mutant C587A-PR, in accordance with our findings showing lack of RU486 capacity to activate p42/p44 MAPK and PI-3K/Akt signaling pathways in these cells. Contrastingly, RU486 has been found to induce proliferation in T47D cells (60) and in T47D-Y cells stably expressing either PR-B or PR-B mutant Ser294A-PR (41), in line with RU486 activation of p42/ p44 MAPK in these latter cells. Differences in PR levels and availability of cell signaling molecules between cells used in the above mentioned studies and in our present work could account for these contrasting results. It is notable that our current results with RU486 further demonstrate that only a PR ligand capable to stimulate PR function as activator of cytoplasmic signaling will drive proliferation of breast cancer cells.
Secondly, one of the most exciting findings of the present study was that unliganded PR modulated the phenotype of both ER-negative (LM3) and ERpositive (T47D-Y) breast cancer cells. Thus, PR-B was able to inhibit basal proliferation of LM3-PR-B and T47D-Y-PR-B cells. Interestingly, several pieces of evidence, including our own work with PR and heregulin (17) , have demonstrated that unliganded steroid receptors could indeed be transcriptionally activated through cross-talk with growth factors signaling pathways (40, 61) . Similarly, expression of unliganded DNA binding mutant C587A-PR resulted in inhibition of basal LM3-C587A-PR and T47D-Y-C587A-PR cell growth. We speculate that growth effects of C587A-PR are due to its ability to activate signaling pathways that, as with PR transcriptional activity, might be stimulated in a ligand-independent manner by growth factors. These signaling pathways could in turn regulate expression of genes involved in proliferation control. Expression of PRBmPro in absence of progestin stimulation also caused cell growth inhibition. Although PR-BmPro is unable to mediate c-Src-dependent signaling activation, it retains transcriptional functions and key phosphorylable residues that might, as in wild-type PR-B, be activated in a ligand-independent manner by cytoplasmic signaling cascades. Our present results are in accordance with pioneering findings of Horwitz and co-workers (38, 39) who recently engineered ER-positive T47D-Y breast cancer cells that express each PR isoform under the control of an inducible promoter. These models allowed them to show that PRs regulate transcript levels in the absence of progesterone and to find extensive ligand-independent regulation of genes involved in regulation of cell-to-cell signaling and adhesion, extracellular matrix, motility and invasion. They also found modulation of cell signaling molecules as well as of genes involved in cell growth and apoptosis.
Thirdly, we found that MPA induced significant reduction of MMP-9, MMP-2, and uPA production in C4HD cells, and of uPA production in LM3-PR-B and LM3-C587A-PR cells. Interestingly, in C4HD cells endogenously expressing both PR-A and PR-B, only MAPK participated in MPA-induced down-regulation of uPA, with no involvement of PI-3K/Akt. Conversely, MPA effect of MMPs activity required functional PI-3K/Akt signaling but no MAPK activation. Contrastingly, in LM3 cells transfected with wild-type PR-B and C587A-PR, both signaling pathways participated in MPA inhibition of uPA activity. To the best of our knowledge, ours is the first description of progestin regulation of MMPs and uPA via nongenomic mechanisms involving activation of MAPK and PI-3K/Akt in breast cancer cells. In addition, these findings indicate that specific signaling pathways, acting in response to progestins to trigger a certain biological response, will likely depend on PR isoforms expressed in a given cell type. Our results agree with recent findings showing differential modulation of cell signaling molecules and genes that participate in motility and invasion by PR-B or PR-A (38, 39) . The presence of ER in C4HD cells could also account for the difference between signaling pathways involved in MPA inhibition of uPA activity because we have found that ER expression could modify MPA capacity to activate signaling pathways. Progesterone has been found to inhibit uPA secretion and both MMP-9 and MMP-2 activities in human endometrial and ovarian carcinoma cells (46) (47) (48) . However, effects of progestins on invasion and metastasis in breast cancer remain poorly studied. Particularly, it has been demonstrated that increased uPA activity levels are positively associated with poor prognosis and that they correlated inversely with estrogen and progesterone receptor status (62) . In a series of recent studies assessing the effect of progesterone on invasive properties and tumor growth in PR-transfected human breast cancer MDA-MB-231 cells, it was found that progesterone strongly down-regulated expression of uPA (63, 64) and MMP-9 (65).
Finally, our present findings for the first time demonstrated that progestins favor development of breast tumor metastasis via PR function as activator of signaling pathways. Our results with PR-BmPro mutant further demonstrate that progestin-activation of c-Src kinase is necessary for MPA induction of metastatic capacity in breast cancer cells.
Therefore, to integrate our present in vitro and in vivo findings, we postulate that unliganded PR expression confers breast cancer cells, both ER-negative and positive, an in vitro less proliferative phenotype, as compared with cells lacking PR expression. Modulation of this behavior occurs by PR function as either both transcription factor and signaling activator (wild-type PR-B), as transcription factor (PR-BmPro) or as activator of p42/p44 MAPK and PI-3K/Akt pathways (C587A-PR). When cells that we have engineered to express PR are exposed to physiological levels of circulating progesterone in the intact animal, different metastatic behaviors will result depending on PR capacity to act as transcription factor or as activator of signaling pathways. On the one hand, cells expressing either wild-type PR-B or C587A-PR, will respond to progesterone with proliferative rates that, according to our in vitro results, will be approximately equal to those of PRnegative cells. In addition, we found that progestins stimulated breast cancer cell survival, as first reported by Moore and co-workers (12) . However, progesterone will significantly reduce uPA activity in PR-transfected cells, as compared with their PRnegative counterparts. The balance between these responses will be a tumor cell with lower metastatic capacity than a PR-negative cell. On the other hand, in cells expressing the mutant PR-BmPro, basal in vitro proliferation was lower as compared with wildtype LM3 cells. However, taking our in vitro results into account, no proliferative response to endogenous progesterone will occur when LM3-PR-BmPro cells are injected in the intact animal. As a result, LM3-PR-BmPro cells showed a metastatic capacity lower not only than cells expressing wild type-PR-B but also than cells transfected with C587A-PR. Therefore, our present findings for the first time provide a mechanistic explanation to the clinical data showing that PR expression in breast tumors, independently of ER status, is a prognostic marker of low aggressiveness with favorable disease-free survival (33, 34) . Interestingly, our previous finding demonstrating that inhibition of uPA activity reduced the incidence and number of experimental and spontaneous lung metastasis in the LM3 model (66) , provides a causal relationship between progestin capacity to inhibit uPA activity and reduced metastatic capacity in LM3 cells expressing PR-B as compared with wild type LM3 cells. However, when PR-B or C587A-PR-positive cells are exposed to exogenous progestin administration, the forcefully proliferative and prosurvival stimulus of progestins, defeats progestin capacity to inhibit protease systems with a final outcome of higher metastasis as compared with cells growing under physiological levels of progesterone. On the contrary, LM3-PRBmPro will not proliferate in response to exogenously administered MPA with consequent no regulation of metastatic behavior in animals treated with MPA. We find these results particularly interesting not only in the light of the recent epidemiological data from the hormonal replacement therapy study in postmenopausal women sponsored by the Women's Health Initiative, evidencing that a combined estrogen plus progestin regimen led to higher rates of breast cancer over the estrogen alone (20, 21) , but also because advanced endometrial and breast cancers are treated with MPA therapeutically, using doses of progestins comparable to those used in our in vivo experiments (67, 68) . It is to note that we have successfully detected different outcomes in the metastatic capacity between cells transiently transfected with PRs and wild-type LM3 cells, because we have employed an in vivo experimental metastasis assay. In our present model, the efficient and rapid steps of arrest and extravasation are completed when the injected cells still express the transfected PRs because we have found that LM3 transiently transfected with wild-type or mutant PRs, express high levels of PR protein 1 wk after transfection. Furthermore, it has long been acknowledged that proteases have a primary effect in the metastatic process facilitating extravasation. Because we have here demonstrated that MPA induced significant reduction of uPA production in LM3-PR-B and LM3-C587A-PR cells, it is likely that when injected into mice with physiological levels of circulating progesterone or into mice treated with MPA, LM3-PR-B and LM3-PR-C587A cells would be less efficient to extravasate to lung than wild-type LM3 cells. Notably, it has recently been shown that proteases not only have a primary effect mediating the extravasation, but also play a crucial role in regulating cell proliferation at the secondary site (reviewed in Ref. 51 ). Because we found that progestins significantly reduce uPA activity in PR-transfected cells, as compared with their PR-negative counterparts, this could result also in early reduced proliferation of PR-transfected cells. As expected, when we examined lung metastasis in mice injected with PR-expressing LM3 cells, using immunohistochemistry, we could not detect PR expression. It is highly probable that through these 28 d, cells have lost PR expression. This finding, however does not invalidate our result because the metastatic capacity of the different LM3 cell types is defined during the first days of the study in which cells retain PR expression. Moreover, similar results regarding PR reduction of lung metastasis were observed at 7 d, when transfected cells still express high levels of PR. Our results with wild-type PR-B or C587A-PRtransfected cells help to explain epidemiological data from the Women's Health Initiative study of the hormonal replacement therapy with a combined estrogen and progestin regimen (20, 21) . We speculate that either the response to progestins of normal epithelial breast cells may be proliferative, as we demonstrated in breast cancer cells, and will finally result in breast tumor development, or that a population of preexisting and perhaps dormant tumor cells in the mammary gland of treated women are stimulated, giving rise to tumor development. Earlier epidemiologic work had also shown that progesterone is not protective in the breast (69) .
Comprehensively, our present findings have unraveled molecular mechanisms of PR ligand-dependent and -independent action in breast cancer. On the one hand, we have for the first time provided a mechanistic support to a recently suggested proposal (41) of therapeutic intervention in PR-positive breast tumors, involving the specific blockage of PR function as activator of signaling to inhibit growth and metastasis. On the other, our findings raise the possibility of considering a gene therapy protocol for PR-negative breast tumors consisting of reexpression in breast cancer cells of a mutant PR that lacks the function of signaling activator.
MATERIALS AND METHODS
Tumors
Hormone-dependent ductal tumor line C4HD originated in female Balb/c mice treated with 40 mg MPA every 3 months for 1 yr and has been maintained by serial transplantation in mice treated with 40 mg sc MPA depot in the opposite flank to tumor inoculum (17, 19, 35, 36) . Virgin female Balb/c mice were raised at the Institute of Biology and Experimental Medicine of Buenos Aires. Transplantation of C4HD tumors to maintain the line was conducted in accordance with the highest standards of animal care as outlined in the National Institutes of Health (N(H) Guide for the Care and Use of Laboratory Animals and procedures were approved by the Institute of Biology and Experimental Medicine Animal Research Committee. C4HD tumor line is of ductal origin, expresses PR and ER (17, 19, 35, 36) and lacks glucocorticoid receptor and EGF-R/ErbB-1 expression (17, 19) .
Cell Culture and Proliferation Assays
Primary cultures of epithelial cells from C4HD tumors growing in MPA-treated mice were performed as previously described (17, 19, 35, 36) . C4HD cells were incubated in DMEM-F12 (without phenol red, with 100 U/ml penicillin, and with 100 g/ml streptomycin), with 0.1% charcoal-stripped fetal calf serum (ChFCS) in the presence and absence of 10 nM MPA, 10 and 100 nM RU486 and MPAϩRU486. To block p42/ p44MAPK activation, 10 M PD98059 or 5 M U0126 (Sigma, St. Louis MO), dissolved in 1:2000 dimethyl sulfoxide (DMSO), was added to cells 90 min before incubation with MPA. To block PI-3K/Akt activation, 1 M Wortmannin or 2 M LY294002 (Sigma) dissolved in 1:2000 DMSO was used. Controls were performed to verify that DMSO did not modify MPA-modulated p42/p44MAPK and PI-3K/Akt activation. T47D human breast cancer cells were obtained from American Type Culture Collection. T47D-Y cells were a generous gift from K. Horwitz (University of Colorado Health Sciences Center, Denver, CO). LM3 murine metastatic mammary tumor cell line was cultured as described (37) . Cell proliferation was evaluated by a ( 3 H)-thymidine incorporation assay after 48-h treatment for C4HD cells in DMEM supplemented with 0.1% ChFCS, and 24-h treatment for LM3 and T47D-Y cells in serum-free medium, as previously described (17, 18) . Assays were performed in octuplicate and differences between control and experimental groups were analyzed by ANOVA followed by Tukey's t test between groups. In former experiments we had demonstrated that thymidine uptake correlates with the number of cells/well (19, 35, 70) .
Transient Transfections
LM3 and T47D-Y cells were transiently transfected with 40 ng of expression plasmids encoding either the human wild-type hPR-B, kindly provided by Dr. K. Horwitz (8) or with a PR-B engineered to contain a point mutation in a conserved cysteine in the first zinc finger of the DNA binding domain (C587A-PR) that was previously performed and characterized by Horwitz and co-workers (43) and lacks the ability to bind to DNA. LM3 cells were also transfected with a mutant PR-B engineered to convert three key prolines (P422A, P423A, P426A) to alanines (PR-BmPro), thus abolishing PR binding to all the SH3 domains and inhibiting activation of c-Src family tyrosine kinases (3). Control cells were transfected with an empty pSG5 vector. LM3 and T47D-Y cells were transfected for 24 h in DMEM supplemented with 5% or 10% ChFCS, respectively, without antibiotics. Fugene 6 transfection reagent technique (Roche Biochemicals, Indianapolis, IN) was used in accordance with manufacturer's instructions. Transfection efficiencies were evaluated using the pEGFP-N1 vector (BD Biosciences Clontech, Palo Alto, CA) and determined by the percentage of cells that exhibited green fluorescence 24 h after transfection. Green fluorescent protein was visualized by direct fluorescence imaging using a Nikon Eclipse E800 confocal laser microscopy system (Nikon Instruments, Inc., Melville, NY). Transfection efficiencies in all three cell types varied between 60-70% (18). After transfection, cells were washed and cultured for 48 h in DMEM before subjection to the indicated treatments. Total cell lysates were then prepared as described below for use in Western blot assays. To study the effect of MPA in proliferation, LM3 and T47D-Y cells were transiently transfected as described above, subjected to the indicated treatments, after which cell proliferation was evaluated by ( 3 H)-thymidine incorporation assay. To analyze MPA-induced transcriptional activation of PR, LM3 and T47D-Y cells were transiently transfected with 40 ng of PR-B, C587A-PR expression vectors or with the pSG5 empty vector and cotransfected with 2 g of a PRE-2X-TATA in the luciferase reporter plasmid pA3-LUC (10) and 1 g of a ␤-galactosidase expression plasmid cytomegalovirus-␤-gal (BD Biosciences Clontech) was used to correct variations in transfection efficiency. Cells were then treated as described, washed once with PBS without calcium and magnesium, and then harvested and lysed in 1ϫ reporter buffer (Promega, Madison, WI) using one freeze-thaw cycle. Protein concentrations were determined using a Bio-Rad kit (Bio-Rad, Hercules, CA). Luciferase results were calculated as the ratio of luciferase activity per unit of ␤-Gal activity. Duplicate samples were analyzed for each datum point.
Clonogenic Assays
LM3 wild-type and LM3 transfected with PR-B, C587A-PR, PR-BmPro, or empty pSG5 vector were cultured at very low density (500 cells/35-mm well) and treated for 5 d with 10 nM MPA or left untreated growing in DMEM supplemented with 10% ChFCS. Cells were washed with PBS (1ϫ), fixed in 10% buffered formalin for 30 min and stained with Giemsa for microscopic observation. Number of colonies containing more than 20 cells was recorded. Assays were performed in triplicate and differences between control and experimental groups were analyzed by ANOVA followed by Tukey's t test between groups.
Western Blot Analysis
Lysates were prepared from C4HD, LM3, and T47D-Y cells subjected to the different treatments described in each experiment. Cells were lysed in buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5% Nonidet P-40, 1 mM Mg 2 Cl, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 5 g/ml pepstatin, 5 g/ml aprotinin, 1 mM sodium orthovanadate, 5 mM NaF, 20 mM sodium molybdate, and 5 mM sodium pyrophosphate. Lysates were centrifuged at 40,000 ϫ g for 40 min at 4 C, and protein content in the supernatant was determined using a Bio-Rad kit. To study the expression of uPA and MMP-9 and -2 in conditioned media, samples were concentrated using Centricon spin columns (Amino, Beverly, MA). Proteins were subjected to SDS-PAGE and electroblotted onto nitrocellulose. Membranes were immunoblotted with the following antibodies: phospho p42/p44 MAPK (E-4), total p42/p44 MAPK (C-14), uPA (M-20), Bcl-x L (s-18), p21 (C-19) all from Santa Cruz Biotechnology (Santa Cruz, CA), phosphoserine 473 Akt, total Akt from Cell Signaling (Beverly, MA), PR (Ab-7), actin (Clone ACTN05) from Neomarkers (Fremont, CA), MMP-2 (Ab-3), MMP-9 (Ab-2) from Oncogene (San Diego, CA). After a washing step, membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Vector Laboratories, Burlingame, CA). Enhanced chemiluminescence was performed according to manufacturer's instructions (Amersham, Arlington Heights, IL).
uPA and MMP Activity Assays
MMP-9 and -2 activities in conditioned media from C4HD cells were studied by measuring collagenolytic activity in 7.5% SDS-polyacryamide gels copolymerized with 0.1% gelatin, as previously reported (71) . After electrophoresis, gels were washed in 50 mM Tris-HCl buffer containing 1% Triton X-100, and incubated for 24 h at 37 C in buffer 50 mM Tris-HCl, 200 mM NaCl, 5 mM CaCl 2 (pH 7.4), for specific activity detection or in the same buffer plus 40 mM EDTA to detect nonspecific activity. Gels were fixed and stained with Coomassie blue R250 in 10% acetic acid and 30% methanol. Activity bands were visualized by negative staining. Gelatinolytic bands were measured with ImageQuant software (Sunnyvale, CA) and referred to protein content. Zymographic analysis of uPA was performed as described (71) . In brief, conditioned media of C4HD and LM3 cells were electrophoresed on 10% SDS polyacrylamide gel containing 0.2% casein and 10 g/ml plasminogen for specific detection or without plasminogen to detect nonspecific activity. After electrophoresis, gels were washed in 50 mM Tris-HCl buffer containing 2% Triton X-100, and incubated for 12 h for C4HD cells or for 2 h for LM3, at 37 C in buffer 20 mM Tris, 15 mM EDTA (pH 8.3) for specific activity detection. Gels were fixed, stained, visualized, and quantified as described for MMPs.
Progesterone and MPA Serum Levels
Mice progesterone serum levels were measured by RIA using a COAT-A-COUNT Progesterone kit (DPC, Diagnostic Products Corp., Los Angeles, CA). Assay sensitivity was 0.02 ng/ml. MPA serum levels in mice bearing MPA pellets were measured by HPLC, as previously described (54) .
In Vivo Studies
Experiments were carried in accordance with the NIH Guide for the Care and Use of Laboratory using virgin female Balb/c mice raised at the Institute Angel Roffo of Buenos Aires. Studies were approved by the Institute Roffo Animal Research Committee. Ability of tumor cells to produce lung metastasis was evaluated using an in vivo experimental metastasis assay (52) . For this purpose, 3 ϫ 10 5 wild-type LM3 cells or the same number of LM3 cells transfected with PR-B, C587A-PR, PR-BmPro, and the empty pSG5 vector, were injected into the tail vein of syngeneic mice. To test the effect of exogenous progestin administration, the same experimental design was carried in animals treated sc with 40 mg MPA depot. At d 7 or 28, mice were killed and the number of superficial lung colonies was counted by an investigator who was blinded to the experimental arm. Comparison of the number of lung metastasis among different groups was done by the nonparametric Kruskal-Wallis test and also by the nonparametrical Mann-Whitney test. Similar results regarding significant differences among groups were obtained with both tests.
